228 related articles for article (PubMed ID: 29156716)
1. Using droplet digital PCR to analyze
Lodrini M; Sprüssel A; Astrahantseff K; Tiburtius D; Konschak R; Lode HN; Fischer M; Keilholz U; Eggert A; Deubzer HE
Oncotarget; 2017 Oct; 8(49):85234-85251. PubMed ID: 29156716
[TBL] [Abstract][Full Text] [Related]
2. Combined Detection of Copy Number Variations of MYCN and ALK using Droplet Digital Polymerase Chain Reaction to Identify High-Risk Patients with Neuroblastoma.
Trivedi T; Panchal K; Bhalala N; Trivedi P; Panchal H
World Neurosurg; 2022 Mar; 159():e48-e57. PubMed ID: 34861448
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma Molecular Risk-Stratification of DNA Copy Number and
Kahana-Edwin S; Cain LE; McCowage G; Darmanian A; Wright D; Mullins A; Saletta F; Karpelowsky J
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282791
[TBL] [Abstract][Full Text] [Related]
4. Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR Reaction.
Peitz C; Sprüssel A; Linke RB; Astrahantseff K; Grimaldi M; Schmelz K; Toedling J; Schulte JH; Fischer M; Messerschmidt C; Beule D; Keilholz U; Eggert A; Deubzer HE; Lodrini M
J Mol Diagn; 2020 Nov; 22(11):1309-1323. PubMed ID: 32858250
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of copy number alterations by liquid biopsy for neuroblastoma.
Shirai R; Osumi T; Sato-Otsubo A; Nakabayashi K; Ishiwata K; Yamada Y; Yoshida M; Yoshida K; Shioda Y; Kiyotani C; Terashima K; Tomizawa D; Takasugi N; Takita J; Miyazaki O; Kiyokawa N; Yoneda A; Kanamori Y; Hishiki T; Matsumoto K; Hata K; Yoshioka T; Kato M
Genes Chromosomes Cancer; 2022 Nov; 61(11):662-669. PubMed ID: 35655408
[TBL] [Abstract][Full Text] [Related]
6. Detection of tumor ALK status in neuroblastoma patients using peripheral blood.
Combaret V; Iacono I; Bellini A; Bréjon S; Bernard V; Marabelle A; Coze C; Pierron G; Lapouble E; Schleiermacher G; Blay JY
Cancer Med; 2015 Apr; 4(4):540-50. PubMed ID: 25653133
[TBL] [Abstract][Full Text] [Related]
7. Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma.
Lodrini M; Graef J; Thole-Kliesch TM; Astrahantseff K; Sprüssel A; Grimaldi M; Peitz C; Linke RB; Hollander JF; Lankes E; Künkele A; Oevermann L; Schwabe G; Fuchs J; Szymansky A; Schulte JH; Hundsdörfer P; Eckert C; Amthauer H; Eggert A; Deubzer HE
Clin Cancer Res; 2022 May; 28(9):1809-1820. PubMed ID: 35247920
[TBL] [Abstract][Full Text] [Related]
8. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
[TBL] [Abstract][Full Text] [Related]
9. ALK amplification and protein expression predict inferior prognosis in neuroblastomas.
Wang M; Zhou C; Sun Q; Cai R; Li Y; Wang D; Gong L
Exp Mol Pathol; 2013 Oct; 95(2):124-30. PubMed ID: 23797004
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
11. Copy number alteration analysis for neuroblastoma using droplet digital polymerase chain reaction.
Ishii Y; Sato-Otsubo A; Takita J; Morio T; Takagi M
Pediatr Int; 2021 Oct; 63(10):1192-1197. PubMed ID: 33462952
[TBL] [Abstract][Full Text] [Related]
12. Alternative pathways of MYCN gene copy number increase in primary neuroblastoma tumors.
Valent A; Guillaud-Bataille M; Farra C; Lozach F; Spengler B; Terrier-Lacombe MJ; Valteau-Couanet D; Danglot G; Lenoir GM; Brison O; Bénard J; Bernheim A
Cancer Genet Cytogenet; 2004 Aug; 153(1):10-5. PubMed ID: 15325088
[TBL] [Abstract][Full Text] [Related]
13. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
[TBL] [Abstract][Full Text] [Related]
14. The absence of a novel intron 19-retaining
Alshareef A; Irwin MS; Gupta N; Zhang HF; Haque M; Findlay SD; Seong BKA; Lai J; Rayis M; Al-Dandan S; Lai R
Oncotarget; 2018 Feb; 9(12):10698-10713. PubMed ID: 29535836
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic mutations of ALK kinase in neuroblastoma.
Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of the MYCN oncogene in neuroblastoma.
Theissen J; Boensch M; Spitz R; Betts D; Stegmaier S; Christiansen H; Niggli F; Schilling F; Schwab M; Simon T; Westermann F; Berthold F; Hero B
Clin Cancer Res; 2009 Mar; 15(6):2085-90. PubMed ID: 19276282
[TBL] [Abstract][Full Text] [Related]
18. Rapid detection of MYCN gene amplification and telomerase expression in neuroblastoma.
Hiyama E; Hiyama K; Yokoyama T; Fukuba I; Yamaoka H; Shay JW; Matsuura Y
Clin Cancer Res; 1999 Mar; 5(3):601-9. PubMed ID: 10100712
[TBL] [Abstract][Full Text] [Related]
19. ARID1B alterations identify aggressive tumors in neuroblastoma.
Lee SH; Kim JS; Zheng S; Huse JT; Bae JS; Lee JW; Yoo KH; Koo HH; Kyung S; Park WY; Sung KW
Oncotarget; 2017 Jul; 8(28):45943-45950. PubMed ID: 28521285
[TBL] [Abstract][Full Text] [Related]
20. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
